European Journal of Pharmacology: Molecular Pharmacology
Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity
References (40)
Memantine is a potent blocker of (NMDA) receptor channels
Eur. J. Pharmacol.
(1989)- et al.
Interaction between glutamatergic and monoaminergic system within the basal ganglia-implications for schizophrenia and Parkinson's disease
Trends Neurosci.
(1990) - et al.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Anal. Biochem.
(1987) - et al.
Effects of 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human post-mortem brain study
Eur. J. Pharmacol.
(1991) - et al.
Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice
Eur. J. Pharmacol.
(1991) - et al.
Noncompetitive excitatory amino acid receptor antagonists
Trends Pharmacol. Sci.
(1990) - et al.
The dopamine and serotonin metabolism in several brain regions of rats
Neurosci. Lett.
(1991) - et al.
The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotonergic and noradrenergic systems
Eur. J. Pharmacol.
(1992) - et al.
Tyrosine hydroxylase: The initial step in norepinephrine biosynthesis
J. Biol. Chem.
(1964) - et al.
A new and highly sensitive voltammetric assay for AADC activity by high-performance liquid chromatography
Anal. Biochem.
(1979)
Locomotor activation induced by MK-801 in the rat: postsynaptic interactions with dopamine receptors in the ventral striatum
Eur. J. Pharmacol.
The effect of a new decarboxylase inhibitor on endogenous and exogenous monoamines
Biochem. Pharmacol.
A rapid and sensitive assay for tyrosine-3-monooxygenase based upon the release of 3H2O and the adsorption of 3[H]-tyrosine by charcoal
Life Sci.
Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons
Brain Res.
Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopaminergic receptors
Eur. J. Pharmacol.
The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
J. Neural Transm.
Central sympathomimetic activity of (+)-5-methyl-10,11-dhydro-5H-dibenzo[a,b]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties
Drug. Dev. Res.
Neuroleptic-induced catalepsy as a model of Parkinson's disease II. Effect of glutamate antagonists
J. Neural Transm.
MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists
Synapse
Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis
J. Neurochem.
Cited by (33)
Synthesis and Neurochemistry of Trace Amines
2016, Trace Amines and Neurological Disorders: Potential Mechanisms and Risk FactorsDopamine D<inf>2</inf>/D<inf>3</inf> receptor binding of [<sup>123</sup>I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging
2014, Nuclear Medicine and BiologyCitation Excerpt :Chronic administration of NMDA receptor antagonists produced progressive changes on neuronal cell count, cell morphology, locomotor activity, stereotypy, ataxia and cognitive deficits in rats and monkey [34–38]. Importantly, in MK-801animal models, alterations of neuron activity and protein expression in striatal, mesolimbic and mesocortical dopamine systems after drug treatment have been confirmed in previous reports [39–41]. Gandolfi et al., 1993 report that chronic treatment with MK-801 decreases dopamine D2 receptor function in rat striatum [42] and our D2R ELISA result indicates chronic MK-801 treatment significantly levels striatal and midbrain D2R concentration down.
Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice
2014, Behavioural Brain ResearchCitation Excerpt :Schizophrenia is a chronic and severe central nervous system disorder affecting approximately 1% of the world population. Previous reports confirm that the noncompetitive NMDA antagonist MK-801 alters neuron activity and protein expression in the dopaminergic system, which has been linked to schizophrenia [41–45]. MK-801 administration has been widely used as to induce schizophrenia-like behaviors in animals such as hyperactivity [46–49], impaired performance in frontal cortex-dependent cognitive tasks [50,51], decreases in social behavior and motivation [52,53], and deficits in sensorimotor gating [54].
[ <sup>123</sup>I]Epidepride neuroimaging of dopamine D <inf>2</inf>/D <inf>3</inf> receptor in chronic MK-801-induced rat schizophrenia model
2012, Nuclear Medicine and BiologyCitation Excerpt :Since MK-801 injection disturbs dopamine system, we evaluate the alteration of tyrosine hydroxylase, the key enzyme in regulation of dopamine synthesis, by anti-tyrosine hydroxylase immunohistochemistry and TH ELISA. Study results show significant increases of TH level, which might indicate huge amount of DA storing in the presynaptic dopamine neurons [23–25,27]. Van Bockstaele et al. reported that a descending glutamatergic pathway projecting from cortical pyramidal neurons to ventral tegmental area (VTA) through γ-aminobutyric acid interneurons inhibits dopamine release from mesolimbic dopamine pathway [28].
MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats
2000, European Journal of PharmacologyOpposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain
2000, Brain ResearchCitation Excerpt :Hadjiconstantinou et al. [20] demonstrated that dopamine receptor antagonists modestly increased DDC activity in mice, but the use of such drugs in dopamine-deficient parkinsonian patients would exacerbate their condition. On the other hand, we and others have found that various N-methyl-d-aspartate (NMDA) receptor antagonists dramatically stimulated DDC in the nigrostriatal dopamine pathway of rats, suggesting the adjunctive use of these compounds may improve pharmacotherapy with l-DOPA in Parkinson’s disease [7,15,16,19]. l-DOPA is not only decarboxylated by DDC in dopaminergic neurones, but also by 5-HTP decarboxylase (hereafter distinguished as 5-HTPDC) in 5-HTergic neurones [3,39].
- ∗
Tel.: 614-292-7232.